Risk Factors for Arthralgias or Myalgias Associated with Quinupristin‐Dalfopristin Therapy

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Pharmacotherapy

• Publication date

  2003-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1592/phco.23.2.159.32078PMID 12587804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arthralgias and myalgias related to quinupristin-dalfopristin administration.

  2001cited by this paper
• Treatment of Vancomycin-Resistant Enterococcal Infections in the Immunocompromised Host: Quinupristin-Dalfopristin in Combination with Minocycline

  2001cited by this paper
• Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.

  2001cited by this paper
• Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.

  2000cited by this paper
• Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

  2000cited by this paper
• Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin–dalfopristin in patients intolerant of or failing prior therapy

  2000cited by this paper
• Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.

  2000cited by this paper
• Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

  1999influential reference
• Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections.

  1999cited by this paper
• Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.

  1999cited by this paper
• The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.

  1999cited by this paper
• Safety and tolerability of quinupristin/dalfopristin: administration guidelines.

  1999cited by this paper
• The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients

  1999cited by this paper
• The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium

  1999cited by this paper
• Quinupristin/Dalfopristin: Spectrum of Activity, Pharmacokinetics, and Initial Clinical Experience

  1995cited by this paper

• New Mutations in cls Lead to Daptomycin Resistance in a Clinical Vancomycin- and Daptomycin-Resistant Enterococcus faecium Strain

  2022cites this paper
• Drug Interactions between Antimicrobial and Immunosuppressive Agents in Solid Organ Transplant Recipients

  2021cites this paper
• Treatment of Vancomycin-Resistant Enterococci: Focus on Daptomycin

  2017cites this paper
• Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy

  2015cites this paper
• The recent evolution of therapeutic weapons

  2015cites this paper
• Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children

  2014cites this paper
• Vancomycin‐Resistant Enterococcus Infections in Solid Organ Transplantation

  2013cites this paper
• Newer Treatment Options for Skin and Soft Tissue Infections

  2012cites this paper
• Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), and Lipopeptides (Daptomycin)

  2010cites this paper
• Novel pharmaceutical molecules against emerging resistant gram-positive cocci.

  2010cites this paper
• Novel pharmaceutical molecules against emerging resistant gram-positive cocci

  2010cites this paper
• Multiply Resistant Gram‐Positive Bacteria: Vancomycin‐Resistant Enterococcus in Solid Organ Transplant Recipients

  2009cites this paper
• against resistant Gram-positive microorganisms

  2008cites this paper
• Novel antibiotics for the management of diabetic foot infections.

  2008cites this paper
• The recent evolution of therapeutic weapons against resistant Gram-positive microorganisms La evolución reciente de las armas terapéuticas contra los microorganismos Gram-positivos

  2008cites this paper
• O uso de drogas ainda experimentais em assistência: extensão de pesquisa, uso compassivo e acesso expandido

  2008cites this paper
• New and Investigational Antimicrobials for the Treatment of Severe Skin Infections

  2008cites this paper
• [Therapeutic uses of investigational drugs: research extension, compassionate use, and expanded access].

  2008cites this paper
• New antimicrobial agents as therapy for resistant gram-positive cocci

  2007cites this paper
• Investigational treatments for postoperative surgical site infections

  2007cites this paper
• Miscellaneous antibacterial drugs

  2007cites this paper
• Management of Community‐Associated Methicillin‐Resistant Staphylococcus aureus Infections in Children

  2006cites this paper
• [Clinically significant toxicity and tolerance of the main antibiotics used in lower respiratory tract infections].

  2006cites this paper
• Toxicité et tolérance cliniquement significatives des principales familles antibiotiques utilisées pour le traitement des infections des voies respiratoires basses

  2006cites this paper
• The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926).

  2006cites this paper
• Treatment options for multidrug-resistant bacteria

  2006cites this paper
• [Medically induced myopathia].

  2006cites this paper
• [Bacterial infections in pediatric cancer patients].

  2005cites this paper
• Safety of newer parenteral antibiotics.

  2005cites this paper
• A re-emerging class of antimicrobial agents: streptogramins (quinupristin/dalfopristin) in the management of multiresistant gram-positive nosocomial cocci in hospital setting.

  2005cites this paper
• Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.

  2004cites this paper
• Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction.

  2004cites this paper
• Comment on letter by Deray

  2004cites this paper
• Newer antibiotics for the treatment of respiratory tract infections

  2004cites this paper
• Myalgia: an uncommon or underestimated side effect of mycophenolate mophetil after transplantation?

  2004cites this paper
• Pharmacoepidemiology and drug safety

  2003cites this paper